<unk>  is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. A 2010 Cochrane review concluded that<unk>  had partial efficacy in "relapse-related clinical outcomes" but no effect on progression of the disease. As a result, it is approved by the FDA for reducing the frequency of relapses, but not for reducing the progression of disability. A 15-year followup of the original trial compared patients who continued with<unk>  to patients who dropped out of the trial. Patients with<unk>  had reduced relapse rates, and decreased disability progression and transition to secondary progressive MS, compared to patients who did not continue<unk> . However, the two groups were not necessarily comparable, as it was no longer a randomized trial. There were no long-term safety issues.
Glatiramer acetate
Riluzole
Fingolimod
Anakinra
Tocilizumab
Benralizumab
Atezolizumab
Satralizumab